Loading...
XSTO
BONEX
Market cap1.64bUSD
Jul 09, Last price  
240.00SEK
1D
7.14%
1Q
4.44%
IPO
697.34%
Name

Bonesupport Holding AB

Chart & Performance

D1W1MN
XSTO:BONEX chart
P/E
111.19
P/S
13.46
EPS
2.16
Div Yield, %
Shrs. gr., 5y
2.48%
Rev. gr., 5y
45.38%
Revenues
1.17b
+30.70%
40,961,00061,755,000104,599,000129,301,00096,623,000155,462,000180,860,000212,885,000328,818,000591,077,000898,727,0001,174,661,000
Net income
142m
+6.28%
-51,065,000-59,555,000-110,190,000-128,869,000-176,405,000-161,060,000-101,412,000-85,531,000-68,167,000245,021,000133,754,000142,154,000
CFO
221m
+236.53%
-45,923,000-65,292,000-81,933,000-107,534,000-171,625,000-163,828,000-100,275,000-83,421,000-46,985,000-18,257,00065,760,000221,304,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
IPO date
Jun 21, 2017
Employees
104
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT